39112-72-6

Basic information

• Product Name: 1,3-Dimethyl-1,2,3,4-tetrahydro-7H-pyrrolo[2,3-d]pyrimidine-2,4-dione
• Synonyms: 1,3-Dimethyl-1,2,3,4-tetrahydro-7H-pyrrolo[2,3-d]pyrimidine-2,4-dione;1,3-Dimethyl-1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione;1,3-dimethyl-7H-pyrrolo[3,2-e]pyrimidine-2,4-dione;1,3-dimethyl-7H-pyrrolo[3,2-e]pyrimidine-2,4-quinone;1H-Pyrrolo(2,3-d)pyrimidine-2,4(3H,7H)-dione, 1,3-dimethyl-;BBV-00026320;BRN 0610903;NSC 79227
• CAS NO: 39112-72-6
• Molecular Formula: C₈H₉N₃O₂
• Molecular Weight: 179.18
• Mol File: 39112-72-6.mol
• Article Data: 2

Chemical Properties

• Melting Point: 300 °C
• Boiling Point: 369.6°Cat760mmHg
• Flash Point: 177.3°C
• Appearance: /
• Density: 1.381g/cm³
• Vapor Pressure: 1.17E-05mmHg at 25°C
• Refractive Index: 1.611
• PKA: 15.80±0.20(Predicted)
• CAS DataBase Reference: 1,3-Dimethyl-1,2,3,4-tetrahydro-7H-pyrrolo[2,3-d]pyrimidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dimethyl-1,2,3,4-tetrahydro-7H-pyrrolo[2,3-d]pyrimidine-2,4-dione(39112-72-6)
• EPA Substance Registry System: 1,3-Dimethyl-1,2,3,4-tetrahydro-7H-pyrrolo[2,3-d]pyrimidine-2,4-dione(39112-72-6)

Safety Data

• Hazardous Substances Data: 39112-72-6(Hazardous Substances Data)

Usage

Type of Compound

Chemical compound

Derivative of

Thalidomide

Usage

Sedative-hypnotic and anxiolytic agent

Mechanism of Action

GABA-A agonist (acts on GABA receptors in the brain)

Medical Applications

Treatment of anxiety, insomnia, and as a pre-medication for anesthesia

Potential Risks

Abuse and addiction

Monitoring

Use should be closely monitored by a healthcare professional

InChI:InChI=1/C8H9N3O2/c1-10-6-5(3-4-9-6)7(12)11(2)8(10)13/h3-4,9H,1-2H3

Upstream product

• 107-20-0 2-chloroethanal 
• 6642-31-5 6-Amino-1,3-dimethylbarbituric acid 
• 128751-18-8 6-Amino-5-(2,2-diethoxyethyl)-1,3-dimethylpyrimidine-2,4-dione 
• 52133-67-2 ethyl 2-cyano-4,4-diethoxybutyrate 
• 97-97-2 chloroacetaldehyde dimethyl acetal 

Downstream Products

• 128751-20-2 7-<2'-Deoxy-3',5'-di-O-(p-toluoyl)-β-D-erythropentofuranosyl>-1,3-dimethylpyrrolo<2,3-d>pyrimidine-2,4-dione 
• 128751-22-4 7-<2'-Deoxy-3',5'-di-O-(p-toluoyl)-α-D-erythropentofuranosyl>-1,3-dimethylpyrrolo<2,3-d>pyrimidine-2,4-dione 
• 119350-47-9 6-benzoyl-1,3-dimethylpyrrolo<2,3-d>pyrimidine-2,4-dione 
• 119350-48-0 6-cinnamoyl-1,3-dimethylpyrrolo<2,3-d>pyrimidine-2,4-dione 
• 39930-51-3 1,3,7-Trimethylpyrrolo<2,3-d>pyrimidine-2,4-dione 
• 119350-50-4 methyl 1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 55307-37-4 1,3-dimethylpyrrolo<2,3-d>pyrimidine-2,4-dione-6-carboxylic acid 

Relevant articles and documents

FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl. Formula (I)